Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Hepatorenal syndrome is caused by a marked vasoconstriction of the renal circulation. It is suggested that the renal vasoconstriction is related to an overactivity of vasoconstrictor systems secondary to a vasodilation of the arterial circulation that causes a reduction in effective arterial blood volume. To test this hypothesis, 16 cirrhotic patients with hepatorenal syndrome were treated with a combination of ornipressin, a potent vasoconstrictor agent, and plasma volume expansion with albumin to improve effective arterial blood volume. The combined treatment was administered either for 3 or 15 days (8 patients each), and the effects on renal function, vasoactive systems, and systemic hemodynamics were assessed. The 3-day treatment with ornipressin and albumin was associated with a normalization of the overactivity of renin-angiotensin and sympathetic nervous systems, a marked increase in atrial-natriuretic peptide levels, and only a slight improvement in renal function. However, when ornipressin and albumin were administered for 15 days, a remarkable improvement in renal function was observed, with normalization of serum-creatinine concentration, a marked increase in renal plasma flow and glomerular filtration rate, and a persistent suppression in the activity of vasoconstrictor systems. However, 3 of 8 patients on 15-day therapy treatment had to be discontinued because of ischemic complications. In conclusion, the decrease in effective arterial blood volume and the activation of vasoconstrictor systems play a crucial role in the pathogenesis of hepatorenal syndrome. Although the prolonged administration of ornipressin combined with plasma volume expansion reverses hepatorenal syndrome, this treatment should be used with great caution in clinical practice because of the risk of ischemic complications.
Guevara
M
M
Liver Unit, Hospital Clínic i Provincial, University of Barcelona, Catalunya, Spain.
Ginès
P
P
Fernández-Esparrach
G
G
Sort
P
P
Salmerón
J M
JM
Jiménez
W
W
Arroyo
V
V
Rodés
J
J
D000328:Adult; D000368:Aged; D005260:Female; D006530:Hepatorenal Syndrome / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D009951:Ornipressin / Q000008:administration & dosage* / Q000627:therapeutic use; D010952:Plasma Substitutes / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000502:physiology; D012709:Serum Albumin / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000008:administration & dosage* / Q000627:therapeutic use
D010952:Plasma Substitutes; D012709:Serum Albumin; D014662:Vasoconstrictor Agents; D009951:Ornipressin; D009638:Norepinephrine